EFFICACY AND SAFETY OF DIFFERENT DOSING REGIMENS OF ALIROCUMAB (STARTING DOSES OF 75 MG EVERY TWO WEEKS AND 150 MG EVERY FOUR WEEKS) VERSUS PLACEBO IN PATIENTS WITH HYPERCHOLESTEROLEMIA NOT TREATED USING STATINS: THE ODYSSEY CHOICE II STUDY  by Stroes, Erik S.G. et al.
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background: Statins upregulate PCSK9 and increased PCSK9 accelerates target-mediated clearance of PCSK9 monoclonal antibodies; 
this may limit sustained efficacy when administered every 4 weeks (Q4W). However, patients (pts) not taking a statin may maintain efficacy 
with Q4W dosing, which could be convenient for some pts. ODYSSEY CHOICE II (NCT02023879) evaluates the efficacy and safety of 
different dosing regimens of alirocumab (ALI) in pts with hypercholesterolemia including pts intolerant to statins, receiving fenofibrate 
(FENO), ezetimibe (EZE) or diet alone.
Methods: Pts were randomized to placebo, ALI 75 mg Q2W or ALI 150 mg Q4W, with dose adjustment at 12 weeks if Week 8 LDL-C 
target levels are not met (Figure). The primary efficacy endpoint is % change in LDL-C from baseline to Week 24; safety will be assessed 
throughout the study.
Results: Efficacy and safety data will be presented at ACC. In total, 233 pts were randomized, 231 treated; ~90% of pts were unable to 
tolerate ≥2 statins due to muscle-related symptoms. At randomization, ~two-thirds of pts received FENO or EZE, ~one-third diet only. 
Preliminary baseline characteristics were: 56% male; mean age 63 yrs; 51% had coronary heart disease; 17% had diabetes; mean LDL-C 
158 mg/dL.
conclusion:  CHOICE II will provide novel ALI efficacy and safety data (including 150 mg Q4W dosing) on background FENO, EZE or diet. 
Since ~90% pts enrolled are intolerant to statins, this study will provide more information on a potential new treatment choice for these pts.
